Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Laxxon Medical
Deal Size : Undisclosed
Deal Type : Partnership
Adare Pharma, Laxxon Partner to Advance 3D Printed Oral Dosage Forms
Details : The partnership aims to leverage Adare's state-of-the-art cGMP facilities and Laxxon's innovative 3D printing technology to bring innovative new oral dosage forms to market.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
September 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Laxxon Medical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Recipient : Ellodi Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ellodi Pharmaceuticals is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare).
Brand Name : APT-1011
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 22, 2020
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Recipient : Ellodi Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 13, 2020
LOOKING FOR A SUPPLIER?